Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$183.34 USD

183.34
910,038

-2.34 (-1.26%)

Updated Oct 7, 2024 04:00 PM ET

After-Market: $183.37 +0.03 (0.02%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand

Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.

Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down

The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.

Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View

Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.

Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View

Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.

The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen

The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen

Focus on Coronavirus Treatments to Boost Biotech Stocks

With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.

Sheraz Mian headshot

Top Research Reports for Intel, Novartis & Toyota

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Novartis (NVS) and Toyota Motor (TM).

Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.

AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL

AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.

Roche's Ocrevus Line Extension Application Moves Forward

Roche's (RHHBY) regulatory applications seeking approval for shorter infusion time for administration of multiple sclerosis drug, Ocrevus, move forward in the United States and Europe.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.

Growth in New Drugs to Give a Boost to Roche (RHHBY) Q1 Sales

Roche's (RHHBY) newer drugs are likely to have combated the biosimilar competition for legacy drugs in the first quarter.

Roche's NDA for SMA Drug Gets Expanded Review From FDA

The FDA stretches the review timeline of Roche's (RHHBY) NDA for risdiplam by three months, which is being evaluated to treat spinal muscular atrophy. A decision is now pending on Aug 24, 2020.

Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal

Glaxo (GSK) set to invest $250 million in Vir Biotechnology. Vir's stock soars.

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis

Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.

The Zacks Analyst Blog Highlights: General Electric, Ford, 3M, Vir and Biogen

The Zacks Analyst Blog Highlights: General Electric, Ford, 3M, Vir and Biogen

Payal Jalan headshot

Diverse Companies Join Forces to Fight Coronavirus Menace

Nervousness related to the coronavirus outbreak is visible across the economies worldwide. Amid the pandemic, many corporates have come together to help contain the outbreak.

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.

J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.

Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.